

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

16 Sep 2026

### Comparing the modified surgical interventions with Probing, Turbinate fracture and Crawford in treatment of congenital obstruction of nasolacrimal duct: a Randomized controlled clinical trial

#### Protocol summary

##### Study aim

Comparison of success rate in modified surgical intervention methods with probing method with turbine fracture and Crawford implantation in the treatment of congenital nasolacrimal duct obstruction

##### Design

4 arm parallel group randomised trial with blinded postoperative care and outcome assessment

##### Settings and conduct

This study will evaluate 4 surgical treatments for the treatment of congenital obstruction of the pure nasolacrimal duct in children under 5 years of age at Farabi hospital. Patients will be examined and examined 4 times after entering the study, and finally, within 6 months after the treatment intervention, they will undergo a complete clinical examination and fluorescein test. The results of this test will be reported positively or negatively, so that the positive result of this test is equal to the openness of the duct and its negative is equivalent to the obstruction of the duct.

##### Participants/Inclusion and exclusion criteria

Inclusion criteria: Children under 5 years of age in whom the diagnosis of congenital nasolacrimal duct obstruction is definitive  
Conditions of non-entry: having accompanying disorders in facial ossification, cleft palate (even hidden), developmental disorders or defects

##### Intervention groups

Patients underwent one of 4 different surgical intervention methods in the treatment of congenital nasolacrimal duct obstruction: Nasolacrimal duct probing surgical intervention with lower nasal turbine rupture And nasolacrimal duct probing surgery with Crawford implantation By nasolacrimal duct probing surgery as a basic method And nasolacrimal duct probing surgery with lower nasal turbine rupture and Crawford implantation as the gold standard method

##### Main outcome variables

Determining the appropriate surgical intervention method with the least invasiveness and the best effectiveness in the treatment of congenital nasolacrimal duct obstruction

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20220120053771N1**

Registration date: **2022-02-08, 1400/11/19**

Registration timing: **prospective**

Last update: **2022-02-08, 1400/11/19**

Update count: **0**

##### Registration date

2022-02-08, 1400/11/19

##### Registrant information

##### Name

Sahel Soltani Shahgoli

##### Name of organization / entity

##### Country

Iran (Islamic Republic of)

##### Phone

+98 21 5542 1080

##### Email address

sahelsoltan93@gmail.com

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2022-03-21, 1401/01/01

##### Expected recruitment end date

2022-09-21, 1401/06/30

##### Actual recruitment start date

empty

**Actual recruitment end date**  
empty

**Trial completion date**  
empty

**Scientific title**  
Comparing the modified surgical interventions with Probing, Turbinate fracture and Crowforded in treatment of congenital obstruction of nasolacrimal duct: a Randomized controlled clinical trial

**Public title**  
Success rate in the treatment of congenital nasolacrimal duct obstruction

**Purpose**  
Treatment

**Inclusion/Exclusion criteria**  
**Inclusion criteria:**  
pure type of congenital nasolacrimal duct obstruction, Age under 5 years, negative fluorosin test without underlying disease or other syndromic disorder, without previous history of nasolacrimal duct intervention or manipulation.  
**Exclusion criteria:**  
Patient / parent dissatisfaction with the study, uncontrollable infection, underlying disease or limitation of anesthesia, concomitant tumors or bleeding disorders, concomitant disorders of facial ossification, cleft palate (even (Secretly)), developmental disorders or defects, problems related to the pituitary gland or Ratke sinus and other abnormalities of the midline of the face.

**Age**  
To 5 years old

**Gender**  
Both

**Phase**  
N/A

**Groups that have been masked**

- Participant
- Outcome assessor
- Data analyser

**Sample size**  
Target sample size: 164

**Randomization (investigator's opinion)**  
Randomized

**Randomization description**  
After determining the patients with the ability to enter the study, a three-digit code will be assigned to each patient, which will introduce the patient in all stages of the study and replace his name and other identity details. Then, a data collection form will be completed for patients and written informed consent will be obtained. In the next stage, patients will be divided into one of 4 intervention groups based on the principles of randomization and blinding and using block randomization method. Patients and evaluators will be unaware of the type of intervention performed during the study and the principles of dual blindness will be observed. Randomization will be based on a predetermined list. May 164 patients will be divided into

4 groups based on sex blocks. The desired list will be prepared by Randlist software.

**Blinding (investigator's opinion)**  
Double blinded

**Blinding description**  
After determining the patients with the ability to enter the study, a three-digit code will be assigned to each patient, which will introduce the patient in all stages of the study and replace his name and other identity details. Patients and evaluators will be unaware of the type of intervention performed during the study and the principles of dual blindness will be observed.

**Placebo**  
Not used

**Assignment**  
Parallel

**Other design features**

**Secondary Ids**  
empty

**Ethics committees**

**1**

**Ethics committee**  
**Name of ethics committee**  
Ethics committee of Tehran University of Medical Sciences  
**Street address**  
Tehran university of medical sciences, Pour sina Ave, keshavarz Blv, Tehran  
**City**  
Tehran  
**Province**  
Tehran  
**Postal code**  
1417653911  
**Approval date**  
2022-03-01, 1400/12/10  
**Ethics committee reference number**  
00000000

## Health conditions studied

### 1

**Description of health condition studied**  
Congenital obstruction of the nasolacrimal duct  
**ICD-10 code**  
H04.53  
**ICD-10 code description**  
Neonatal obstruction of nasolacrimal duct

## Primary outcomes

### 1

**Description**  
Comparison of success rate in modified surgical intervention methods with probing method with turbine

fracture and Crawford implantation in the treatment of congenital nasolacrimal duct obstruction

#### **Timepoint**

patients will be examined for the success of the intervention as well as the complications of the intervention, a day after the intervention,. At 3 months and 6 months after the surgery, patients will be re-evaluated for the visual system and fluorocin test will be performed, and the results of follow-up and examination at times 0, 3 and 6 (months) will be evaluated and compared.

#### **Method of measurement**

At each follow-up, patients will undergo a complete evaluation of the visual system and perform a fluorescein test

### **Secondary outcomes**

empty

### **Intervention groups**

#### **1**

##### **Description**

Intervention group: Nasolacrimal duct probing surgery with rupture of the lower nasal turbine

##### **Category**

Treatment - Surgery

#### **2**

##### **Description**

Intervention group: Nasolacrimal duct probing surgery with Crawford implantation

##### **Category**

Treatment - Surgery

#### **3**

##### **Description**

Intervention group: Nasolacrimal duct probing surgery as a basic procedure

##### **Category**

Treatment - Surgery

#### **4**

##### **Description**

Intervention group: Nasolacrimal duct probing surgery with lower nasal turbine fracture and Crawford implantation as the gold standard method

##### **Category**

Treatment - Surgery

### **Recruitment centers**

#### **1**

##### **Recruitment center**

**Name of recruitment center**

Farabi hospital

**Full name of responsible person**

Sahel Soltani Shahgoli

##### **Street address**

Farabi hospital, South Kargar Ave, Qazvin Sqr

##### **City**

Tehran

##### **Province**

Tehran

##### **Postal code**

1336616351

##### **Phone**

+98 21 5540 0003

##### **Email**

sahelsoltan93@gmail.com

### **Sponsors / Funding sources**

#### **1**

##### **Sponsor**

###### **Name of organization / entity**

Tehran University of Medical Sciences

###### **Full name of responsible person**

Mohammad Ali Sahraian

###### **Street address**

South Kargar, Farabi hospital

###### **City**

Tehran

###### **Province**

Tehran

###### **Postal code**

1336616351

###### **Phone**

+98 21 5540 0003

###### **Email**

sahelsoltan93@gmail.com

##### **Grant name**

##### **Grant code / Reference number**

##### **Is the source of funding the same sponsor organization/entity?**

Yes

##### **Title of funding source**

Tehran University of Medical Sciences

##### **Proportion provided by this source**

100

##### **Public or private sector**

Public

##### **Domestic or foreign origin**

Domestic

##### **Category of foreign source of funding**

empty

##### **Country of origin**

##### **Type of organization providing the funding**

Academic

### **Person responsible for general inquiries**

##### **Contact**

###### **Name of organization / entity**

Tehran University of Medical Sciences

###### **Full name of responsible person**

Sahel Soltani Shahgoli

###### **Position**

Resident  
**Latest degree**  
Medical doctor  
**Other areas of specialty/work**  
Ophthalmology  
**Street address**  
Farabi hospital, South Kargar Ave, Qazvin Sqr  
**City**  
Tehran  
**Province**  
Tehran  
**Postal code**  
1336616351  
**Phone**  
+98 21 5540 0003  
**Fax**  
**Email**  
sahelsoltan93@gmail.com

## Person responsible for scientific inquiries

### Contact

**Name of organization / entity**  
Tehran University of Medical Sciences  
**Full name of responsible person**  
Sahel Soltani Shahgoli  
**Position**  
Resident  
**Latest degree**  
Medical doctor  
**Other areas of specialty/work**  
Ophthalmology  
**Street address**  
Farabi hospital, South Kargar Ave, Qazvin Sqr  
**City**  
Tehran  
**Province**  
Tehran  
**Postal code**  
1336616351  
**Phone**  
+98 21 5540 0003  
**Fax**  
**Email**  
sahelsoltan93@gmail.com

## Person responsible for updating data

### Contact

**Name of organization / entity**  
Tehran University of Medical Sciences  
**Full name of responsible person**  
Sahel Soltani Shahgoli  
**Position**  
Resident  
**Latest degree**  
Medical doctor

**Other areas of specialty/work**  
Ophthalmology  
**Street address**  
Farabi hospital, South Kargar Ave, Qazvin Sqr  
**City**  
Tehran  
**Province**  
Tehran  
**Postal code**  
1336616351  
**Phone**  
+98 21 5540 0003  
**Fax**  
**Email**  
sahelsoltan93@gmail.com

## Sharing plan

### Deidentified Individual Participant Data Set (IPD)

Undecided - It is not yet known if there will be a plan to make this available

### Study Protocol

Undecided - It is not yet known if there will be a plan to make this available

### Statistical Analysis Plan

Undecided - It is not yet known if there will be a plan to make this available

### Informed Consent Form

Undecided - It is not yet known if there will be a plan to make this available

### Clinical Study Report

Yes - There is a plan to make this available

### Analytic Code

Undecided - It is not yet known if there will be a plan to make this available

### Data Dictionary

Undecided - It is not yet known if there will be a plan to make this available

### Title and more details about the data/document

After the end of the study, the results of the study of the consequences and data analysis will be published in the form of an article with details and working methods.

### When the data will become available and for how long

Access period starts 6 months after the results are published

### To whom data/document is available

After printing the results, everyone will have access to the documents

### Under which criteria data/document could be used

After printing the results, everyone will have access to the documents

### From where data/document is obtainable

By sending an email to the responsible author

### What processes are involved for a request to access data/document

By sending an email to the responsible author

### Comments